XOMA Royalty Corporation SEC Filings

Owen Hughes, who is listed as Chief Executive Officer and a Director of XOMA Royalty Corp, reported transactions dated 09/19/2025. The filing shows acquisition of 35,567 Performance Stock Units (PSUs) that each represent a contingent right to one share of common stock and vest upon the common stock reaching a specified price per share. After these derivative and related non‑derivative entries, Mr. Hughes is reported to beneficially own 132,714 shares on a direct basis. The filing also records a disposition of 2,000 Depository Shares of an 8.375% Series B Cumulative security. The form is signed by an attorney‑in‑fact and includes a Power of Attorney exhibit.

Thomas M. Burns, SVP, Finance & CFO of XOMA Royalty Corp (symbol: XOMAP), reported equity activity related to vested performance stock units and subsequent share sales to cover taxes. He was credited with 11,846 common shares from PSUs that vest when the stock reaches a specified price, increasing his direct common-stock holdings to 34,409 shares. Shortly thereafter he sold 4,300 shares at $35.98 and two small blocks of 15 shares each at $36.93 and $36.81, reducing his direct holdings to roughly 30,079 shares.

He also reports 6,130 shares held indirectly through a 401(k) plan and disposal of 2,000 depository shares and 2,000 series A preferred shares. The filing explains the sales were to satisfy tax withholding on PSU settlement, and the PSUs convert one-for-one into common stock with an exercisable date of 05/18/2026.

Maricel P. Montano, Chief Legal Officer and Director of XOMA Royalty Corp (XOMA), reported insider transactions dated 09/19/2025. The filing shows acquisition of 3,033 Performance Stock Units (PSUs) and 3,033 shares of Common Stock recorded as acquired with $0 price, with PSUs vesting upon the company's common stock reaching a specified price per share. After the reported transactions the filing lists 12,134 shares of common stock and 11,316 derivative units beneficially owned following the transactions. The PSUs have a stated date exercisable of 05/18/2026 per the filing. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Montano on 09/23/2025.

XOMA Royalty Corp. reporting person Maricel Perea Montano, Chief Legal Officer and director, was granted 23,450 Performance Stock Units (PSUs) on 08/12/2025. Each PSU converts to one share of XOMA common stock if a specified stock price target is met. The PSUs are shown as acquired with a $0 exercise price and are recorded as 23,450 shares beneficially owned following the award, held in a direct form.

The PSUs become eligible for issuance on 05/16/2026 subject to achieving the stated price condition. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/14/2025. No sale or cash payment is reported; this filing documents a contingent equity award tied to future stock performance.

Maricel P. Montano is identified as Chief Legal Officer and a director-level reporting person for XOMA Royalty Corp (XOMAP). The Form 3 dated 08/12/2025 indicates no securities are beneficially owned by the reporting person. The submission was signed on behalf of Montano by an attorney-in-fact, Thomas Burns, on 08/14/2025. This filing is an initial ownership statement showing the officer/director relationship but reporting no direct or indirect holdings.

XOMA Royalty Corporation filed a Current Report announcing it issued a press release that reports the company's financial results for the fiscal quarter ended June 30, 2025. The filing states the full text of that press release is attached as Exhibit 99.1 and is incorporated by reference into the report.

The Form also notes that the information in the Form and the attached Exhibit is not to be deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings except as expressly stated. The Form itself does not present financial figures; readers must consult Exhibit 99.1 for the results and highlights.

XOMA Royalty Corporation is a biotech royalty aggregator, recently reincorporated to Nevada in May 2025. As of June 30, 2025 total assets were $223,456 thousand and total unrestricted and restricted cash and cash equivalents were $78,485 thousand. Management concluded its cash balance is sufficient to fund planned operations, commitments, and contractual obligations for at least one year.

For the three months ended June 30, 2025 total income and revenues were $13,129 thousand and net income was $9,191 thousand, compared with net income of $15,985 thousand in the prior-year quarter. For the six months ended June 30, 2025 total income and revenues were $29,041 thousand and net income was $11,558 thousand. Income from operations was $4,603 thousand for the quarter versus an operating loss of $10,079 thousand in the comparable prior quarter. Stockholders' equity increased to $72,435 thousand from $61,902 thousand at December 31, 2024.

The company paid $20,614 thousand for a BioInvent contract-based intangible asset during the period, recorded long-term debt of $102,201 thousand and convertible preferred stock of $20,019 thousand. The Company reclassified its Series X Convertible Preferred Stock as mezzanine (temporary) equity and restated comparative balances, which management judged immaterial.